BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Singh A, Mahajan R, Kedia S, Dutta AK, Anand A, Bernstein CN, Desai D, Pai CG, Makharia G, Tevethia HV, Mak JW, Kaur K, Peddi K, Ranjan MK, Arkkila P, Kochhar R, Banerjee R, Sinha SK, Ng SC, Hanauer S, Verma S, Dutta U, Midha V, Mehta V, Ahuja V, Sood A. Use of thiopurines in inflammatory bowel disease: an update. Intest Res 2022;20:11-30. [PMID: 33845546 DOI: 10.5217/ir.2020.00155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Park SH, Park SH. Personalized medicine in inflammatory bowel disease: Perspectives on Asia. J Gastroenterol Hepatol 2022. [PMID: 35726657 DOI: 10.1111/jgh.15919] [Reference Citation Analysis]
2 Park JB, Park SH. Prevention of postoperative recurrence in Crohn's disease: the never-ending story. Intest Res 2022;20:279-80. [PMID: 35916018 DOI: 10.5217/ir.2022.00081] [Reference Citation Analysis]
3 Lee JW, Kim ES. Is the Long-term Disease Course of Elderly-Onset Ulcerative Colitis Different from That of Non-Elderly-Onset Ulcerative Colitis? Gut Liver 2021;15:639-40. [PMID: 34521775 DOI: 10.5009/gnl210403] [Reference Citation Analysis]
4 Fries W, Demarzo MG, Navarra G, Viola A. Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks? Drugs Aging 2022;39:441-52. [PMID: 35641753 DOI: 10.1007/s40266-022-00943-0] [Reference Citation Analysis]
5 Park CH, Park JH, Jung YS. Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Pers Med 2022;12:507. [PMID: 35330505 DOI: 10.3390/jpm12030507] [Reference Citation Analysis]
6 Chang JY, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precis Future Med 2021;5:151-63. [DOI: 10.23838/pfm.2021.00128] [Reference Citation Analysis]